Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Promoter DNA hypermethylation is the key epigenetic mechanism by which tumor suppressor genes are inactivated in human cancer. The discovery of the importance of this mechanism has spurred the development of a number of approaches to identify genes silenced by DNA hypermethylation in cancer. One of the most useful of these approaches is an epigenomic reactivation screening strategy that combines treatment of cancer cells in vitro with DNA methyltransferase and/or histone deacetylase inhibitors, followed by global gene expression analysis using microarrays, to identify upregulated genes. This approach is most effective when complemented by microarray analyses to identify genes repressed in primary tumors. Epigenomic reactivation screening has a number of key advantages over direct analysis of cancer-associated DNA methylation changes; most notably, it directly identifies genes in which epigenetic changes lead to altered gene expression. An increasing number of studies have utilized epigenomic reactivation screening to discover novel tumor suppressor genes in cancer. The results of some of the most recent studies are highlighted in this review.

Original languageEnglish (US)
Pages (from-to)231-241
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number3
StatePublished - Jun 1 2007

Fingerprint

Epigenomics
DNA
Genes
Neoplasms
Microarray Analysis
Tumor Suppressor Genes
Gene Expression
Histone Deacetylase Inhibitors
Methyltransferases
DNA Methylation

Keywords

  • 5-Aza-2′-deoxycytidine
  • Cancer
  • DNA methylation
  • Epigenetics
  • HDAC inhibitor
  • Microarray
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. / Karpf, A. R.

In: Current Opinion in Molecular Therapeutics, Vol. 9, No. 3, 01.06.2007, p. 231-241.

Research output: Contribution to journalReview article

@article{581ebec3ceff4aceb1380a0384b5fb0b,
title = "Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer",
abstract = "Promoter DNA hypermethylation is the key epigenetic mechanism by which tumor suppressor genes are inactivated in human cancer. The discovery of the importance of this mechanism has spurred the development of a number of approaches to identify genes silenced by DNA hypermethylation in cancer. One of the most useful of these approaches is an epigenomic reactivation screening strategy that combines treatment of cancer cells in vitro with DNA methyltransferase and/or histone deacetylase inhibitors, followed by global gene expression analysis using microarrays, to identify upregulated genes. This approach is most effective when complemented by microarray analyses to identify genes repressed in primary tumors. Epigenomic reactivation screening has a number of key advantages over direct analysis of cancer-associated DNA methylation changes; most notably, it directly identifies genes in which epigenetic changes lead to altered gene expression. An increasing number of studies have utilized epigenomic reactivation screening to discover novel tumor suppressor genes in cancer. The results of some of the most recent studies are highlighted in this review.",
keywords = "5-Aza-2′-deoxycytidine, Cancer, DNA methylation, Epigenetics, HDAC inhibitor, Microarray, Tumor suppressor gene",
author = "Karpf, {A. R.}",
year = "2007",
month = "6",
day = "1",
language = "English (US)",
volume = "9",
pages = "231--241",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "3",

}

TY - JOUR

T1 - Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer

AU - Karpf, A. R.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Promoter DNA hypermethylation is the key epigenetic mechanism by which tumor suppressor genes are inactivated in human cancer. The discovery of the importance of this mechanism has spurred the development of a number of approaches to identify genes silenced by DNA hypermethylation in cancer. One of the most useful of these approaches is an epigenomic reactivation screening strategy that combines treatment of cancer cells in vitro with DNA methyltransferase and/or histone deacetylase inhibitors, followed by global gene expression analysis using microarrays, to identify upregulated genes. This approach is most effective when complemented by microarray analyses to identify genes repressed in primary tumors. Epigenomic reactivation screening has a number of key advantages over direct analysis of cancer-associated DNA methylation changes; most notably, it directly identifies genes in which epigenetic changes lead to altered gene expression. An increasing number of studies have utilized epigenomic reactivation screening to discover novel tumor suppressor genes in cancer. The results of some of the most recent studies are highlighted in this review.

AB - Promoter DNA hypermethylation is the key epigenetic mechanism by which tumor suppressor genes are inactivated in human cancer. The discovery of the importance of this mechanism has spurred the development of a number of approaches to identify genes silenced by DNA hypermethylation in cancer. One of the most useful of these approaches is an epigenomic reactivation screening strategy that combines treatment of cancer cells in vitro with DNA methyltransferase and/or histone deacetylase inhibitors, followed by global gene expression analysis using microarrays, to identify upregulated genes. This approach is most effective when complemented by microarray analyses to identify genes repressed in primary tumors. Epigenomic reactivation screening has a number of key advantages over direct analysis of cancer-associated DNA methylation changes; most notably, it directly identifies genes in which epigenetic changes lead to altered gene expression. An increasing number of studies have utilized epigenomic reactivation screening to discover novel tumor suppressor genes in cancer. The results of some of the most recent studies are highlighted in this review.

KW - 5-Aza-2′-deoxycytidine

KW - Cancer

KW - DNA methylation

KW - Epigenetics

KW - HDAC inhibitor

KW - Microarray

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=34250645467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250645467&partnerID=8YFLogxK

M3 - Review article

C2 - 17608021

AN - SCOPUS:34250645467

VL - 9

SP - 231

EP - 241

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 3

ER -